Pembrolizumab-induced dermatomyositis in a patient with metastatic melanoma
Abstract
Pembrolizumab is an immune checkpoint blockade monoclonal antibody targeting the programmed cell death protein 1 (PD-1), recently approved for the treatment of patients with unresectable or metastatic melanoma [ [1] Robert C. Schachter J. Long G.V. Arance A. Grob J.J. Mortier L. et al. Pembrolizumab versus Ipilimumab in advanced melanoma. N Engl J Med. 2015; 372: 2521-2532https://doi.org/10.1056/NEJMoa1503093 Crossref PubMed Scopus (3447) Google...
Paper Details
Title
Pembrolizumab-induced dermatomyositis in a patient with metastatic melanoma
Published Date
Nov 1, 2018
Journal
Volume
104
Pages
227 - 230
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History